ALXN News and Press, Alexion Pharmaceuticals Inc. From 06/28/20

If 2020 has taught Wall Street and investors anything -- aside from the fact that stock market crashes are an inevitable part of the investing process -- it's that staying the course with great companies is a smart move. Uncertainty tied to the unprecedented coronavirus disease 2019 (COVID-19...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Alexion Pharmaceuticals (ALXN) is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, ...

- Ongoing Phase 3 study demonstrated PK non-inferiority of ULTOMIRIS SC versus ULTOMIRIS IV at Day 71 - - Preliminary safety data consistent with the known safety profile of ULTOMIRIS - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced topline results from a Phase 3 st...

– Funding supports efforts by National Organization for Rare Disorders (NORD Ⓡ ) and Global Genes to address needs of the rare disease community arising from COVID-19 pandemic – The Alexion Charitable Foundation, launched by Alexion Pharmaceuticals, Inc. (NASDAQ:AL...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Bank of America Virtual Napa Biotech Conference on Monday, June 22nd, 2020 at 2:00 p.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alex...

While the market has recovered impressively from its late-March low, it's not too late to step into stocks if you missed out. Investors should take such a step very carefully, of course, as the sheer speed and distance of the advance has left some names vulnerable to profit taking. At the other ...

Investment Thesis The patent disputes over its leading revenue generator have taken its toll on Alexion Pharmaceuticals, Inc. ( ALXN ), with its share price lagging the peers as the company attempts to diversify the top-line. The recent acquisitions, driven by the rising cash flows and low...

What an absolutely wild ride it's been for investors over the past three-plus months. It took a mere 33 calendar days between Feb. 19 and March 23 to send the benchmark S&P 500 down by 34%, and the subsequent 11 weeks for the index to gain the vast majority of its losses back. We've simply...

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...